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According to the World Health Organization (WHO), 
there is emergence of new viral infections which 
indicates a serious threat to public health. In the last 
twenty years, several viral epidemics such as the 
severe acute respiratory syndrome coronavirus (SARS-
CoV) in 2002 to 2003, and H1N1 influenza in 2009, the 
Middle East respiratory syndrome coronavirus (MERS-
CoV) first identified in Saudi Arabia in 2012 have been 
recorded.[1] The CoVs (coronavirus) have become the 
major   pathogens   of   emerging   respiratory  disease  
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outbreaks that cause illness ranging from the common 
cold to more severe diseases.[2] They are a large family 
of single-stranded RNA viruses (+ssRNA) that can be 
isolated in different animal species.[3] 
The 2019–20 corona virus pandemic is an ongoing 
pandemic of corona virus disease 2019 (COVID-19), 
caused by severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2).[4] In genetic terms, Chan 
et al. have proven that the genome of the new HCoV, 
isolated from a Cluster-patient with atypical 
pneumonia after visiting Wuhan, had 89% nucleotide 
identity with bat SARS-like-CoVZXC21 and 82% with 
that of human SARS-CoV.[5] For this reason, the new 
virus was called SARS-CoV-2. A novel coronavirus 
(2019-nCoV) is a new strain that has not been 
previously identified in humans. The outbreak started 
in Wuhan, Hubei province, China, on 31 December 
2019. The WHO declared the outbreak as a Public 
Health Emergency of International Concern (PHEIC) on 
30th January 2020 and recognized it as a pandemic on 
11 March 2020.[6,7] Because of its contagious nature, it 
has quickly spread globally and a large number of 
individual are getting infected at the same time thus 
A B S T R A C T  
Recently, there is an emergence and outbreak of a new viral disease i.e. COVID-19 which is spreading 
faster than ever in many different regions of the world. COVID-19 is an infectious disease caused by a 
newly discovered coronavirus which spreads primarily through droplets of saliva or discharge from the 
nose when an infected person coughs or sneezes. It is a respiratory disease and most infected people 
will develop mild to moderate symptoms but according to WHO data, maximum number of patients 
related to Covid-19 are associated with common symptoms including fever, dry cough, shortness of 
breath, tiredness and sore throat. This new virus seems to be very contagious and has quickly spread 
globally. At present there are no specific vaccine or treatment for Covid-19 in contemporary science, 
however it is known that Ayurveda provides a potential holistic approach from many centuries and 
proven to be the most efficient tool in health management system. Therefore, an effort has been 
made to find possible Ayurvedic comparison to the current most prevalent COVID-19 disease based on 
particular signs and symptoms and to explain its management. 
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creating great strain over public health. Studies 
revealed significant overlapping of imaging features of 
COVID-19 with SARS and MERS.[8]  
As it spread over different regions of the world as 
pandemic, in Ayurvedic context, it can be correlated 
to Janapadoddhvansa Vikara (mass destruction).[9] As 
per etiopathogenesis, it comes under Agantuja Jvara 
(variety of fever occurring due to external factors) 
with special reference to Abhisangaja Jvara (microbial 
etiology).[10] Clinical symptoms of Covid-19 are similar 
to Vishama Jvara (with special reference to 
Chaturthaka Jvara) when there is involvement of Rasa 
(lymph), Asthi (bone) and Majja Dhatu (bone marrow 
tissue).[11] 
There is an urgent need of prevention and control of 
this disastrous combination of newly occurring 
disease, but unfortunately, no integrative measures 
have been validated in human trials as effective 
specifically for COVID-19. Hence, an attempt has been 
made in this article to find possible Ayurvedic 
comparison to the current most prevalent Covid-19 
disease based on particular signs and symptoms and 
to explain the role of Rasayana Chikitsa, Krimihara 
Chikitsa and Vyadhi Pratyanika Chikitsa to combat 
COVID-19. 
AYURVEDIC PERSPECTIVE OF COVID-19 
In context of Janapadoddhvansa Vikara 
As Covid-19 has evolved itself into a pandemic, 
affecting a large population irrespective of their 
physical features, dietary patterns, psychological 
attributes etc., therefore in Ayurvedic context, it can 
be correlated to Janapadoddhvansa Vikara. Acharya 
Charaka has described epidemic disease as 
Janapadoddhvansa (mass destruction). The Mula 
(causative factor) of Janapadoddhvansa is Adharma 
(unrighteousness) and Yoni (origin) is Pragyaparadha 
(intellectual error)[12] due to which four components 
i.e. Vayu (air), Jala (water), Desha (habitat) and Kala 
(seasons) get Vikrita (vitiated or deranged) resulting in 
destruction of entire Janapada (community).[13] 
Acharya Sushruta mentioned that even Prakrita 
(normal) ritvadi components may result in  
Janapadoddhvansa due to Bhutabhishangaja 
(microbial attack).[14] 
In context of Aupasargika Roga 
Acharya Sushruta has mentioned Aupasargika Roga 
(communicable disease) and their mode of 
transmission in Kustha Nidana. These are contagious 
diseases which spread through direct contact or 
contaminated objects of patients, by physical contact, 
expired air, sharing bed, clothes or eating with 
affected person in same vessels and these diseases 
spread from person to person. Jvara is one among 
these disease.[15] COVID-19 is also highly contagious 
evidenced by its rapid transmission along with many 
exported cases across the world. 
In context of Agantuja Jvara 
Fever caused by external factors is called Agantuja 
Jvara. Among 4 types of Agantuja Jvara, COVID-19 can 
be grouped under Abhishangaja Jvara due to attack of 
Bhuta (microbes).[16]  
In context of Vishama Jvara 
Acharya Sushruta considered that 
“Agantushchanubandho Hi Prayashovishama Jvare” 
means Aagantuja Karana (external cause) is 
responsible for Vishama Jvara.[17] According to 
Acharya Sushruta “Kechid Bhutabhishangottham 
Bruvate Vishama Jvaram”- means in Vishama Jvara 
there is involvement of microbes.[18] Acharya 
Chakrapani have also commented on Vishama Jvara 
as Bhutanubhandha and further explained that in 
Vishama Jvara, firstly there is microbial invasion and 
clinical symptoms appears later[19] which is justified by 
incubation period concept of COVID-19. 
Symptoms of Covid-19 
The most common symptoms of COVID-19 are fever, 
tiredness, and dry cough. Some patients may have 
aches and pains, nasal congestion, runny nose, sore 
throat or diarrhea. These symptoms are usually mild 
and begin gradually. Around one out of every six 
people who gets COVID-19 becomes seriously ill and 
develops difficulty breathing. Older people, and those 
with underlying medical problems like high blood 
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pressure, heart problems or diabetes, are more likely 
to develop serious illness.[20] 
As per above clinical features of Covid-19, most of the 
symptoms are present in Vishama Jvara with special 
reference to Chaturthaka Jvara. Though the classical 
features of Chaturthaka Jvara doesn’t match with 
COVID-19, but in the context of Vishama Jvara, it is 
explained that Pravritti Kala of Jvara depends on the 
site of the Doshas in specific Dhatu, therefore when 
Jvara infiltrate in to bones and bone marrow i.e. Asthi 
and Majja Dhatu it is called Chaturthaka Jvara. It is 
very dangerous and also brings on a simultaneous 
attack of complications.[21] As in the general 
pathological process of Jvara, Rasa (lymphatic fluid) is 
considered as prime and primary Dhatu and that 
phenomena also occurred in this condition. 
Chaturthaka Jvara is of two types - when Kapha is 
vitiated, calf region is afflicted first and when Vata is 
vitiated, head is afflicted first.[22] 
Sign and symptoms manifested if vitiated Doshas 
causing Jvara are located in Asthi Dhatu (bone tissue)  
are Vireka (diarrhea), Vamana (vomiting), Asthi Bheda 
(pain in joints), Prakujana (cooing sound as present in 
pneumonia), Shvasa (difficulty in breathing), Gatra 
Vikshepa (movement of body and limb)[23] and  if 
located in Majja Dhatu (bone marrow) are Hikka 
(hiccup), Shvasa (difficulty in breathing), Kasa 
(cough),Tama Darshana (comatose condition), 
Marma Cheda (affection of Vital organs), Antardaha 
(fever) and Bahirshaityam (cold extremities).[24] Most 
of the symptoms noticed in corona virus disease 
(Covid-19) has close resemblance with Asthi and 
Majjagata Jvara as mentioned in Table 1.  
Table 1: Symptoms of Asthigata and Majjagata Jvara 































Ayurvedic treatment principle of COVID-19 
As epidemics of viral diseases occur at a gap of years, 
these infections are not at the priority among the 
research community and that is the reason why there 
is as yet no effective vaccine or treatment for 
emerging viral diseases like covid-19 in contemporary 
science.[25] Due to the viral nature of disease and its 
fast spread it has become a challenge before medical 
fraternity to fight this pandemic. It is important to 
stop the progression of disease at earliest possible 
stage. Stopping the progression of the disease is the 
most ideal step of controlling the disease, moreover 
increasing immunity by various means are also 
required,[26] so holistic approach of Ayurveda provide 
a potential remedy to combat this health emergency. 
Rasayana therapy 
Use of Rasayana therapy is mentioned by Acharya 
Charaka as treatment modality.[27] To maintain health 
and to cure disease through Rasayana therapy along 
with main treatment is the unique approach of 
Ayurveda.[28] As there is severe immune injury 
revealed by pathogenesis of COVID-19, these 
rejuvenation therapies may play significant role in 
treatment. Moreover, prevention is always better 
than cure and immunity plays a major role in 
prevention of disease and in diseased condition also. 
Acharya Charaka mentioned that chances of having 
disease is determined by Vyadhikshamtva power 
(immunity).[29] Rasayana is a preventive therapy which 
provides strength and immunity and is helpful in 
maintaining health along with fight against infection.  
From above description it is quite clear that the 
function of the immune system is critical in the human 
response to COVID-19. 
Krimihara Chikitsa 
In Ayurveda, Krimi is broadly described for worms and 
micro-organism. These may be Drishta or Adrishta.[30] 
Hence Krimihara Chikitsa may have potential to kill or 
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restrict growth of microbes (virus, bacteria, and 
fungi). Acharya Charaka describes three different 
modalities[31] which may be effective in COVID-19 
treatment. 
1. Nidana Parivarjana  
To avoid the known disease causing factors is known 
as Nidana Parivarjana which is mentioned as 
Pradhana Chikitsa (first and foremost treatment) 
among all.[32] For reducing the chances of getting 
infection, knowledge of disease causing factors is 
must. In context of covid-19, isolation and social 
distancing are given most weightage by WHO to limit 
the spread of disease. Use of mask, handwashing, 
sanitization are also other important preventive 
measures which are also  described as a part of 
Dincharya (daily routine) mentioned in classical text. 
2. Apakarshana 
It is process of removing disease producing entities by 
using various therapeutic processes like Vamana 
(therapeutic emesis), Virechana (therapeutic 
purgation).[33]  As covid-19 resides in throat for few 
hours, if daily practice of gargling with hot water and 
mild Vamana with Saindhava Lavana is done it will 
restrict the attachment of Spike protein of corona 
virus to host ACE2 receptors and further 
pathogenesis. This may be employed depending on 
clinical presentation of disease. 
3. Prakrtivighata 
Use of specific drug which stop growth of disease 
producing pathogens by creating an unfavorable 
condition for their growth, which is an efficient 
method of managing disease known as 
Prakritivighata. As nature of virus is Kapha-Vataja 
(Kaphaja  due to its structural composition that 
includes 4 types of proteins and capacity of making 
attachment to substratum and resides in 
Kaphasthana[34] Urahpradesha, Griva, Shiro Pradesha 
and Vataja due to rapid spread, transmission by touch 
and air, rapid division and pathogenesis capability). 
Hence the drugs having Kapha-Vata Shamaka 
properties (i.e. Katu, Tikta rasa, Laghu, Ruksha, 
Tikshna Guna and Ushna Virya) may restrict growth of 
pathogen (COVID-19). 
Vyadhi Pratyanika Chikitsa 
In this treatment, Aushadha which pacify a particular 
disease are administered. Clinical symptoms of 
COVID-19 resemble with Chaturthaka Jvara when it 
enters in Asthi and Majja Dhatu. Hence, treatment 
protocol of Chaturthaka Jvara described in Jvara 
Chikitsa by Acharya Charaka may prove beneficial.[35] 
20 ml Kwatha (decoction) made from 5 gm Guduchi 
[Tinospora cordifolia (Thunb.) Miers], 5 gm Amalaki 
(Emblica officinalis Gaertn) and 5 gm Musta (Cyperus 
rotundus Linn.) may constitute the treatment of 
Chaturthaka Jvara. The pharmacological properties of 
above drugs are mentioned in Table 2.[36] 

















Family Name Menispermaceae Euphorbiaceae Cyperaceae 







Virya Ushna Sheeta  Sheeta 
Vipaka Madhura Madhura Katu 




Properties of Guduchi 
The water-soluble fraction of 95% ethanolic extract of 
T. cordifolia plant has shown significant antipyretic 
activity.[37] In another experimental study, antipyretic 
effects have been reported in the hexane- and 
chloroform-soluble portions of T. cordifolia stems.[38] 
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The extract has also exhibited in vitro inactivating 
property against hepatitis B and E surface antigens in 
48 to 72 hours.[39] The alcoholic and aqueous extracts 
of T. cordifolia are reported to have beneficial effects 
on the immune system and have been tested 
successfully for their immunomodulatory activity.[40] 
TCE (T. cordifolia extract) has been shown to 
demonstrate a decrease in the recurrent resistance of 
HIV virus thus improving the therapeutic outcome.[41] 
Anti-HIV effects of TCE was revealed by reduction in 
eosinophil count, stimulation of B lymphocytes, 
macrophages and polymorphonuclear leucocytes and 
hemoglobin percentage thus, revealing its promising 
role of application in management of the disease.[42] 
Properties of Amalaki 
Studies on Amalaki demonstrate in vitro antiviral and 
antimicrobial properties.[43] Amalaki has antioxidant, 
cytoprotective,[44] anti-hepatitis, anti-cancer, anti-
tumour activity.[45] Various experimental studies also 
have suggested antioxidant[46] and hypolipidemic 
effects[47] of Amla. In another study, the 
immunomodulatory activity of aqueous extract of E. 
officinalis was reported. It showed that E. officinalis-
treated mice had significantly higher antisheep RBC 
(red blood cell) titer and DTH ( delayed type 
hypersensitivity) reaction compared to the control. 
This was concluded because of significant increase in 
WBC count and lymphocyte distribution in E. 
officinalis-treated mice, suggesting its ability to 
stimulate haemolymphopoetic system.[48] 
Properties of Musta  
Totaloligomeric flavonoid extract of C. rotundus L. 
possessed a broad spectrum of pharmacological 
properties such as antioxidant, antimutagenic, 
antigenotoxic, antimicrobial, anticancer, and 
neuroprotective properties.[49] Data showed very 
promising hepatoprotective and anti-HBV potential of 
C. rotundus rhizome extracts in vitro. Taken together, 
while the n-butanol and aqueous fractions exhibited 
hepatoprotective as well as anti-HBV activities, the 
ethyl acetate fraction showed only antiviral effect.[50] 
A study reported significantly (p < 0.001) high anti-
pyretic activity of 95% alcoholic extract of C. rotundus 
against pyrexia induced in albino rats through 
injection of suspension of dried Brewer’s yeast in gum 
acacia in normal saline subcutaneously.[51] The pure 
compounds isolated  from the tubers of C. rotundus, 
the root bark of Zanthoxylum gilletii, and the root 
bark of Margaritaria discoidea to demonstrate the 
anti-malarial activity.[52]  Activity-guided investigation 
of C. rotundus tubers led to the isolation of 
sesquiterpenes such as patchoulenone, caryophyllene 
alpha-oxide, 10,12-peroxycalamenene and 4,7-
dimethyl-1-tetralone. These compounds exhibited 
anti-malarial activity.[53] Hydro-alcoholic extract of C. 
rotundus along with 41 Egyptian medicinal plants 
were screed for anti-viral activity. The extract was 
tested on three viruses—HSV (herpes simplex-1 virus), 
POLIO (poliomyelitis-1 virus) and VSV (vesicular 
stomatitis virus). Determination of anti-viral activity 
was done by end point titration technique. C. 
rotundus showed virucidal activity against Herpes 
Simplex Virus.[54] 
CONCLUSION 
“Na Hi Sarva Vikaraṇam Namato Asti Dhruva Sthiti” 
means there are innumerable diseases according to 
variations in etiology and location, so it is not possible 
to give standard names to all. Hence after acquiring 
complete knowledge of nature of disease, its 
pathogenesis, location and etiological factors, one 
should rationally follow Ayurvedic principle for 
diagnosis of disease as well as its treatment protocol 
as mentioned in classical text. Guduchi, Amalaki and 
Musta are economic, classical and available all over 
India. Their properties can be further evaluated by 
clinical findings or trials so further research is required 
in order to reach into more conclusive evidences. 
There is need for developing guidelines to smartly and 
efficiently tackle these new emerging viral diseases 
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